• Hero Banner
  • ACVCACVC
  • DVM 360
  • Fetch DVM 360Fetch DVM 360
DVM 360
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
By Role
AssociatesOwnersPractice ManagerStudentsTechnicians
Subscriptions
dvm360 Newsletterdvm360 Magazine
News
All News
Association
Breaking News
Education
Equine
FDA
Law & Ethics
Market Trends
Medical
Products
Recalls
Regulatory
Digital Media
dvm360 LIVE!™
Expert Interviews
The Vet Blast Podcast
Medical World News
Pet Connections
The Dilemma Live
Vet Perspectives™
Weekly Newscast
dvm360 Insights™
Publications
All Publications
dvm360
Firstline
Supplements
Top Recommended Veterinary Products
Vetted
Clinical
All Clinical
Anesthesia
Animal Welfare
Behavior
Cardiology
CBD in Pets
Dentistry
Dermatology
Diabetes
Emergency & Critical Care
Endocrinology
Equine Medicine
Exotic Animal Medicine
Feline Medicine
Gastroenterology
Imaging
Infectious Diseases
Integrative Medicine
Nutrition
Oncology
Ophthalmology
Orthopedics
Pain Management
Parasitology
Pharmacy
Surgery
Toxicology
Urology & Nephrology
Virtual Care
Business
All Business
Business & Personal Finance
Buying or Selling a Practice
Hospital Design
Leadership & Personal Growth
Personnel Management
Practice Finances
Practice Operations
Technology
Wellbeing & Lifestyle
Continuing Education
Conferences
Live Conferences
Conference News
Conference Proceedings
Resources
CBD in Pets
Contests
Veterinary Heroes
Partners
Spotlight Series
Team Meeting in a Box
Toolkit
Top Recommended Veterinary Products
Vet to Vet
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us

© 2023 MJH Life Sciences and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Advertisement
By Role
  • Associates
  • Owners
  • Practice Manager
  • Students
  • Technicians
Subscriptions
  • dvm360 Newsletter
  • dvm360 Magazine
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Equine infectious ulcerative keratitis uveitis (Proceedings)

August 1, 2011
Susan Keil, DVM, MS, DACVO

Uveitis classification: any cause of blood-ocular barrier breakdown

Introduction

     o Moon Blindness, Periodic Ophthalmia

     o Most common cause of blindness in horses

          • 2-5% of US horses

     o Recurrent episodes of intraocular inflammation separated by quiescence

     o What causes ERU?

          • Genetic

          • Environment

          • Cause of initial uveitis

     o Etiology debatable, but agreement that a dysregulated ocular immune response causes the disease

          • Positive corticosteroid effects

          • Inflammatory recurrences

          • Lack of antibiotic tx success

     o Unilateral vs bilateral disease

          • May be either

          • Recurrences may be either

          • If 2+ years pass without disease in second eye, vastly reduced chance of developing disease

Uveitis Classification: any cause of blood-ocular barrier breakdown

     o Primary: any etiology causing inflammation

          • Trauma: blunt vs penetrating

          • Infectious

               √ Bacterial: Brucella, Borrelia burgdorferi, Leptospira, Rhodococcus equi, Streptococcus

               √ Viral: EHV-1, EHV-2, Equine influenza, EVA, Parainfluenza type 3

               √ Parasitic: Onchocerca, Strongylus, Toxoplasma

          • Miscellaneous: endotoxemia, neoplasia, septicemia, tooth root abscess

     o Equine Recurrent Uveitis

          • Two or more episodes observed

          • Two+ years w/out an episode diminishes risk

          • Labeled: active / acute, quiescent, or end-stage

          • Three clinical syndromes

               √ Classic

                    • Most common

                    • Inflammation of iris, ciliary body, and choroid and adjacent cornea, anterior chamber, lens, vitreous, retina

                    • Attacks become more frequent / more severe

                    • Sequelae include blindness, phthisis bulbi, cataract, synechia

               √ Insidious

                    • Low grade inflammation not outwardly painful

                    • Gradual destructive effect

                    • Draft and appaloosa breeds

               √ Posterior

                    • Vitreous, retina, choroid and some anterior segment associated inflammation

                    • Blindness, vitreal cloudiness, retinal detachments

                    • Warmbloods, Europeans, draft breeds

Advertisement

Clinical Appearance

     o No gender preference

     o Variable clinical signs

     o Over half of cases present before 12 years of age

     o Anterior Segment

          • Pain

          • Epiphora

          • Blepharospasm

          • Miosis*

               √ Unless dilated or synechia present

          • Hypotony

               √ IOP = 5 – 15 mmHg

          • Aqueous flare

          • Iris color change

               √ Dull, rubeosis

          • Corneal edema

          • Deep, short perilimbal vessels common

          • Fluorescein dye test – negative uptake

          • Calcific band keratopathy w/chronic disease

          • Uncommon – corneal cellular infiltrates, extensive neovascularization

     o Posterior Segment

          • Difficult to assess – anterior segment inflammation

          • Vitritis (debris, murky, "glow")

          • Vitreal liquefaction / floaters / traction bands

          • Fundus obscured

Chronic End Stage Disease

     o Posterior synechia, capsular pigment, focal / diffuse cataracts

     o Lens luxation / subluxation

     o Secondary glaucoma

     o Retinal Detachment

     o Chorioretinal scarring (peripapillary region)

          • Non-tapetal area: small, circular focal depigmentation with central hyperpigmentation

          • Wing-shaped hypopigmentation nasal and temporal to disc = Butterfly Lesion

DDX / Diagnostics

     o Dx determined by characteristic clinical signs and historical clinical bouts

     o DDX

          • Corneal diseases (ulcer, abscess, foreign body, neoplasia, immune-mediated, viral)

          • Non-ERUveitis

          • Glaucoma

     o Diagnostic tests:

          • CBC/Profile

          • Leptospiral serology: questionable value / tests previous exposure

          • Aqueous humor / serum leptospiral serology more helpful

               √ Microagglutination titers (MAT)

               √ Positive C value: aqueous MAT value / serum MAT value

                    • Suggests intraocular production of antibodies against the organism

          • Equine leukocyte antigen (ELA) typing: may help determine genetic susceptibility

          • Fecal

          • Lyme and EVA titer / Western blot analysis

Leptospira

     o Linked to spontaneous ERU around the world

     o Initial report linking leptospirosis to ERU in 1940 in Germany

     o Abundant research generated since then

     o Precise pathogenesis of disease (induction, role of organism in uveitis) remains poorly understood

          • 1985 – UF detected AB specific to L. interrogans

          • 1985 – Argentina demonstrated antigentic relationship between cornea and Leptospira, suggesting molecular mimicry

Appaloosa Horses

     o Significantly higher risk: 8.3 times higher than other breeds combined

     o Clinically distinct from classic ERU cases

     o Often insidious course without bouts of pain

     o Age of onset variable

     o Secondary complications / sequelae biggest problem

     o Bilateral – 80% of cases

     o Glaucoma affected 21%

     o Sequelae: posterior synechia, iris color change, cataracts, luxation/subluxation, vitritis, retinal detachments, phthisis bulbi, blindness

     o Coat color pattern: significant finding

          • Light base coats with focal darker spots**

               √ Leopard pattern

          • Dark base coats with light rump blanket least likely affected

     o Equine MHC may play a factor in susceptibility

Medical Treatment

     o Two main goals

          • Reduce inflammation: corticosteroids and NSAIDs

          • Reduce discomfort: mydriatic- cycloplegic

     o Medication categories

          • Topical steroids

               √ Prednisolone acetate 1%

                    • Indication – potent anti-inflammatory with excellent penetration

                    • Dose – q 1 to 6 hours

                    • Risk – predisposes to corneal fungal infection

               √ Dexamethasone 0.5-1.0%

                    • Indication – potent anti-inflammatory with excellent penetration

                    • Dose – q 1 to 6 hours

                    • Risk – predisposes to corneal fungal infection

          • Topical NSAIDs

               √ Flurbiprofen 0.03% / Diclofenac 0.1%

                    • Indication – anti-inflammatory with good penetration

                    • Dose – q 1 to 6 hours

                    • Risk – decreases corneal epithelialization

          • Mydriatic – cycloplegic

               √ Atropine 1%

                    • Indication – cycloplegic / mydriatic (minimize synechia / pain relief)

                    • Dose – q 6 to 24 hours

                    • Risk – may predispose to colic by decreasing gut motility

               √ Phenylephrine 10%

                    • Indication – use combined with atropine; not great in horse but may provide some added help (alpha agonist)

          • Systemic anti-inflammatory medications

               √ Flunixin meglumine

                    • Indication – potent ocular anti-inflammatory

                    • Dose – 0.5 mg/kg PO, IV, IM x 5 days, then 0.25 mg / kg

                    • Risk – long term use may predispose to gastric / renal toxicity

               √ Phenylbutazone

                    • Indication – anti-inflammatory

                    • Dose – 4.4 mg/kg PO, IV

                    • Risk- long term use may predispose to gastric / renal toxicity

               √ Dexamethasone (Azium)

                    • Indication – potent anti-inflammatory

                    • Dose – 5-20 mg / day PO or 2.5 – 5.0 mg/day IM

                    • Risk – frequent side effects, laminitis formation so use with caution and as a last resort, taper off dose, alter management (decrease confinement, stress, starches while increasing forage and access to paddocks / pastures)

               √ Prednisone

                    • Indication – potent anti-inflammatory

                    • Dose – 100-300 mg / day PO, IM

                    • Risk - see dexamethasone

          • Subconjunctival injection

               √ Trimacinolone

                    • Indication – potent anti-inflammatory, 7-10 day duration of action

                    • Dose – 1-2 mg

                    • Risk – severe predisposition for bacterial or fungal keratitis; cannot remove once administered

          • Intravitreal antibiotic

               √ Gentocin – 4 mg

          • Systemic antibiotic?

               √ Doxycycline - 12 mg/kg PO BID for one month

               √ Enrofloxacin - 7.5 mg/kg PO QD for one month

Surgical Treatment

     o Suprachoroidal cyclosporine sustained-release implants

          • Constant therapeutic drug delivery to affected tissues

          • By-passes some of blood-ocular barriers

          • Reduces / eliminates need for regular tx by owner

          • Release rates well below toxic drug levels

          • Patient convenience

          • Blocks transcription of IL-2 production and the responsiveness of the T-

     o Rapamycin injection

Prognosis

     o See chronic end-stage disease

     o Corneal ulcers

     o Pthisis bulbi

     o Enucleation

     o Poor for sight: 50-60% of ERU cases in studies experienced blindness in one or two eyes

     o Appaloosas that were seropositive for Leptospirosis had the worst visual prognosis

Related Content:

Ophthalmology
Beware of neurogenic keratoconjunctivitis sicca caused by otic medications
Beware of neurogenic keratoconjunctivitis sicca caused by otic medications
Veterinary Eye Center of NYC to offer free eye exams to local working animals
Veterinary Eye Center of NYC to offer free eye exams to local working animals
UC Davis study on eye diseases in kittens
UC Davis study on eye diseases in kittens

Advertisement

Latest News

Locoregional analgesia for pain management in veterinary medicine

Outside toxicology experts can save pets’ lives

Lyon College School of Veterinary Medicine names founding dean

Morris Animal Foundation funds study on environmental toxins and lymphoma

View More Latest News
Advertisement